TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia
description
Transcript of TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia
![Page 1: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/1.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
1/33db 7/5/2011
TERZA SESSIONEL’ANZIANO CARDIOPATICO CON
CO-MORBILITÀ
Infarto miocardico e Broncopneumopatia
Ostruttiva
Daniele Bertoli
![Page 2: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/2.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
2/33db 7/5/2011
COPD
• The 4th leading cause of death in the USA (behind heart desease, cancer, cerebrovascular disease)
• In 1990, COPD was ranked 12th as a burden of disease; by 2020 it is projected to rank 5°
• The majority of patients with COPD die from cardiovascular disorders or cancer, not respiratory disease
![Page 3: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/3.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
3/33db 7/5/2011
![Page 4: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/4.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
4/33db 7/5/2011
COPD: Definition
• lung disease characterized by chronic obstruction of lung airflow that interferes with normal breathing and is not fully reversible.
• The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs.
• The more familiar terms 'chronic bronchitis' and 'emphysema' are no longer used, but are now included within the COPD diagnosis.
• COPD is not simply a "smoker's cough" but an under-diagnosed, life-threatening lung disease.
![Page 5: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/5.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
5/33db 7/5/2011
COPD: Definition• diagnosis is confirmed by spirometry• COPD should be considered in any patient
who has symptoms of cough, sputum production, or dyspnea and/or a history of exposure to risk factors for the disease
• Chronic cough and sputum production often precede the development of airflow limitation by many years, although not all individuals with cough and sputum production go on to develop COPD
![Page 6: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/6.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
6/33db 7/5/2011
PARAMETRI SPIROMETRICI
• FEV1 o VEMS (Volume espiratorio forzato in 1 secondo) = quantità di aria emessa nel primo secondo di espirazione forzata
• FVC (Capacità Vitale Forzata) = quantità massima di aria (misurata in litri) che può essere espulsa in un’espirazione forzata dopo un’ispirazione completa.
• FEV1/FVC = Un valore inferiore al 70% indica un deficit ostruttivo e alta probabilità di BPCO.
![Page 7: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/7.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
7/33db 7/5/2011
Spirometria Normale e TracciatoSpirometrico di Pazienti con BPCO
![Page 8: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/8.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
8/33db 7/5/2011
Classificazione spirometrica di gravitàdella BPCO basata sul VEMS
post-broncodilatatore
![Page 9: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/9.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
9/33db 7/5/2011
Heart disease and COPD
• The most common cardiac abnormalities in patients with COPD are cor pulmonale and pulmonary hypertension
• The prevalence of atrial fibrillation, atherosclerosis, and CHF is also high among patients with COPD
![Page 10: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/10.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
10/33db 7/5/2011
Atherosclerosis and COPD
• Although some of the association between COPD and atherosclerosis may be the result of common risk factors such as tobacco use, epidemiological evidence suggests that impaired lung function is a risk factor for increased cardiovascular death independent of tobacco use
![Page 11: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/11.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
11/33db 7/5/2011
The Relationship Between Reduced Lung Function and Cardiovascular Mortality - A Population-Based Study and a Systematic Review of the LiteratureChest 2005;127;1952-1959
![Page 12: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/12.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
12/33db 7/5/2011
The Relationship Between Reduced Lung Function and Cardiovascular Mortality - A Population-Based Study and a Systematic Review of the LiteratureChest 2005;127;1952-1959
![Page 13: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/13.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
13/33db 7/5/2011
Metaanalysis of studies that reported RR of cardiovascular mortality based on FEV1 quintiles.
Chest 2005;127;1952-1959
![Page 14: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/14.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
14/33db 7/5/2011
Metaanalysis of studies that reported RR of cardiovascular mortality among nonsmokers
Chest 2005;127;1952-1959
![Page 15: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/15.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
15/33db 7/5/2011
Relationship between FEV 1, smoking status, and OR for cardiovascular mortality for current smoker (dark grey squares), ex-smoker (white
squares), and never smoker (light grey squares)
Young RP , Hopkins R , Eaton TE . Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes . Eur Respir J . 2007; 30(4): 616- 622
![Page 16: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/16.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
16/33db 7/5/2011Circulation 2003;107:1514-1519
![Page 17: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/17.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
17/33db 7/5/2011Circulation 2003;107:1514-1519
![Page 18: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/18.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
18/33db 7/5/2011
Association between chronic obstructive pulmonary diseaseand systemic inflammation: a systematic review and a metaanalysis Thorax 2004;59:574–580
Relationship between C-reactive protein (CRP) and COPD
![Page 19: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/19.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
19/33db 7/5/2011
Association between chronic obstructive pulmonary diseaseand systemic inflammation: a systematic review and a metaanalysis Thorax 2004;59:574–580
Relationship between fibrinogen and COPD
![Page 20: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/20.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
20/33db 7/5/2011
Association between chronic obstructive pulmonary diseaseand systemic inflammation: a systematic review and a metaanalysis Thorax 2004;59:574–580
Relationship between leucocytes and COPD
![Page 21: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/21.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
21/33db 7/5/2011
C-reactive Protein As a Predictor of Prognosis in ChronicObstructive Pulmonary Disease
Am J Respir Crit Care Med 175. 250–255, 2007
![Page 22: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/22.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
22/33db 7/5/2011
COPD could be considered as part of a “chronic systemic inflammatory syndrome.”• cardiovascular diseases
• lung cancer
• peripheral skeletal muscle dysfunction
• nutritional abnormalities
• osteoporosis
• increased prevalence of diabetes
• chronic kidney diseaseCHEST 2011; 139(1):165–173
![Page 23: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/23.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
23/33db 7/5/2011
Cardiovascular Safety of Tiotropium in Patients With COPD
Chest 2010;137;20-30
![Page 24: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/24.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
24/33db 7/5/2011
Cardiovascular Safety of Tiotropium in Patients With COPD
Chest 2010;137;20-30
![Page 25: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/25.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
25/33db 7/5/2011
J. Am. Coll. Cardiol. 2006;47;2554-2560;
![Page 26: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/26.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
26/33db 7/5/2011
Long-term mortality according to COPD and statin use in patients with peripheral arterial disease
van Gestel YR , Hoeks SE , Sin DD , et al . Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease . Am J Cardiol . 2008 ; 102 ( 2 ): 192 - 196
![Page 27: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/27.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
27/33db 7/5/2011
![Page 28: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/28.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
28/33db 7/5/2011
Beta-Blockers• Patients with COPD are at increased risk of CAD, and ß-
blockers play a pivotal role in the management of cardiovascular diseases.
• There is a general reluctance to use these substances in patients with COPD because of an unfounded fear of inducing bronchospasm.
• A large Cochrane review revealed that cardioselective beta-blockers did not adversely affect the FEV1 or induce respiratory symptoms compared with placebo, independent of the severity of the COPD.
• Given the demonstrated efficacy of b -blockers in treating CAD and CHF, the benefit of these medicaments outweighs the side effects and they should not be withheld from patients with COPD
![Page 29: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/29.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
29/33db 7/5/2011
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis
of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
European Journal of Heart Failure (2009) 11, 292–298
![Page 30: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/30.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
30/33db 7/5/2011Arch Intern Med. 2010;170(10):880-887
![Page 31: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/31.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
31/33db 7/5/2011Arch Intern Med. 2010;170(10):880-887
![Page 32: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/32.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
32/33db 7/5/2011Arch Intern Med. 2010;170(10):880-887
![Page 33: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/33.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
33/33db 7/5/2011
Take Home Messages
• La BPCO è un fattore di rischio cardiovascolare
• E’ probabile che meccanismi fisiopatologici simili, di tipo infiammatorio, siano presenti nella BPCO e nella malattia aterosclerotica
• Le terapie pneumologiche più efficaci (tiotropio in particolare) sono efficaci anche per ridurre il rischio CV dei pazienti con BPCO
• Le terapie cardiologiche più efficaci (statine, beta-bloccanti, inibitori RAAS) sono efficaci anche nella BPCO
![Page 34: TERZA SESSIONE L’ANZIANO CARDIOPATICO CON CO-MORBILITÀ Infarto miocardico e Broncopneumopatia](https://reader035.fdocuments.in/reader035/viewer/2022062322/5681515b550346895dbf7f21/html5/thumbnails/34.jpg)
SC Cardiologia Clinica RiabilitativaSarzana
34/33db 7/5/2011
OSPEDALE SAN BARTOLOMEO DI SARZANA